In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galen licenses US rights to Lilly's Serafem

Executive Summary

For a cash consideration of €294mm ($295mm), Galen Holdings licensed exclusive US sales and marketing rights to Eli Lilly's Sarafem (fluoxetine hydrochloride), a treatment for premenstrual dysphoric disorder (PMDD). It paid about 3.5 times the drug's annual sales.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies